PEG-MGF

Also known as: PEGylated MGF, PEGylated Mechano Growth Factor

A PEGylated version of MGF with extended half-life for systemic muscle effects.

Overview

PEG-MGF is mechano growth factor (MGF) modified with polyethylene glycol (PEG) to extend its half-life from minutes to hours. This allows for systemic administration rather than local injection, making it more practical for whole-body muscle support.

Mechanism of Action

Same mechanism as MGF - activates muscle satellite cells. PEGylation protects from rapid degradation and extends circulation time. Allows systemic effects rather than just local injection site effects.

Pharmacokinetics

Half-life extended to several hours (vs minutes for MGF). Subcutaneous administration. Systemic distribution.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Muscle Support

Dose

200-500 mcg

Frequency

2-3x weekly

Duration

4-6 weeks

Systemic administration

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Growth synergy

Synergy: Satellite activation plus differentiation

Rationale: GH support

Synergy: Complete growth hormone axis support

Research Areas

Muscle GrowthSystemic RecoverySatellite Cell ActivationBody CompositionAnti-AgingPerformance

Key Research Findings

  • 1Extended half-life allows systemic use
  • 2Activates satellite cells throughout body
  • 3More practical dosing than standard MGF
  • 4Still limited human research

Side Effects & Contraindications

Reported Side Effects

  • Hypoglycemia (possible)
  • Injection site reactions
  • Limited long-term data

Contraindications

  • Active cancer
  • Uncontrolled diabetes

Safety Considerations

Research compound. Longer half-life may increase systemic effects. Monitor for hypoglycemia. Limited safety data.

Storage Requirements

Refrigerate 2-8°C after reconstitution

Scientific References

Quick Reference

Sequence
MGF + PEG modification
Molecular Weight
~5-10 kDa (depending on PEG size)
Half-Life
Several hours
Bioavailability
Injectable
Research Stage
preclinical
Administration
Subcutaneous injection